

22249

# United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/938,114

08/23/2001

Chun Wang

265/132

**CONFIRMATION NO. 1975** 

Date Mailed: 09/10/2001

**FORMALITIES LETTER** 

\*OC000000006540499\*

LYON & LYON LLP 633 WEST FIFTH STREET SUITE 4700 LOS ANGELES, CA 90071

OCT 0 9 2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE

**DISCLOSURES** 

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated

below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no n w matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



Patent

Attorney Docket: 265/132

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:			) · )	Group Art U	nit:	1653
Invento	or:	Wang Chun et. al.	)	Examiner:	to be a	ssigned
Serial 1	No.:	09/938,114	)			
Filed: August 23, 2001			)	•		
For: An Antithrombosis Enzyme from the Snake Venom of Agkistrodon Acutus						
		· F				

# TRANSMITTAL OF SEQUENCE LISTING

Box Sequence Commissioner for Patents Washington, D.C. 20231

Sir:

#### I. DOCUMENTS ENCLOSED:

In response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCES AND/OR AMINO ACID SEQUENCE DISCLOSURES, which was mailed by the Patent Office on September 10, 2001, enclosed are:

Submission of Sequence Listing under 37 C.F.R. §1.821(e)

A copy of the Notice to Comply With Requirements For Patent Applications
Containing Nucleotide Sequences And/Or Amino Acid Sequence Disclosures

LA-212422.1

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 5, 2001

Date of Deposit

Rachel Marquez

Attorney Docket: 265/132

II.	REC	<b>DUEST FOR</b>	<b>EXTENSION</b>	OF TIME:

The proceedings herein are for a patent application and the provisions of 37 CFR § 1.136 apply.

Applicant(s) petitions for an extension of time under 37 CFR § 1.136 [fees: 37 CFR § 1.17(a)(1)-(5)] for the total number of months checked below:

EXTENSION (months)		FEE FOR SMALL ENTITY	FEE FOR OTHER THAN SMALL ENTITY				
	one month	\$55.00		\$110.00			
Ш	two months	\$200.00		\$400.00			
	three months	\$460.00		\$920.00			
	four months	\$720.00		\$1,440.00			
	five months	\$980.00		\$1,960.00			
			Fee	\$0.00			

If any extension fee is required, please consider this a petition therefor.

## III. FILING FEES

Applicant claims small entity status pursuant to 37 CFR 1.27.

BASIC FILING	FEE:							\$0.00
Total Claims		-	20	=	0	х	\$18.00	\$0.00
Independent Claims		-	3	=	0	Х	\$80.00	\$0.00
Multiple Dependent Claims	\$270	(if	applio	cable	:)			\$0.00
Surcharge 37 CFR § 1.16(e)	\$130	(if	applio	cable	;)			\$0.00
TOTAL OF ABOVE CALCULATIONS				\$0.00				
Reduction by ½ for Filing by S 1.28.	mall Entit	y. No	ote 37	CF	R §§	1.9,	1.27,	\$0.00
Extension of Time (from above	)							\$0.00
Assignment \$40 (if applicab	le)						$\boxtimes$	\$0.00
TOTAL FEES	SUBMIT	TED	HER	REW	TH			\$0.00

#### IV. METHOD OF PAYMENT OF FEES:

A check in the amount of $$0.00$ is enclosed to cover the above fee(s).
Charge Lyon & Lyon's Deposit Account No. 12-2475 in the amount of

Attorney Docket: 265/132

 $\boxtimes$ The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. 12-2475 for any fees required under 37 CFR §§ 1.16, 1.17 and 1.445 that are not covered, in whole or in part, by a check enclosed herewith and to credit any overpayments to said Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

/8andra S. Fujiyama Reg. No. 46,713

22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP **Suite 4700** 633 W. Fifth Street Los Angeles, CA 90071 (213) 489-1600